Allergic rhinitis-Allergic rhinitis is an allergic inflammation of the nasal airways.
In this slide we can get info about its causes,symptoms,prevention & treatment.This slide helps people to know about this disease.
Allergic rhinitis-Allergic rhinitis is an allergic inflammation of the nasal airways.
In this slide we can get info about its causes,symptoms,prevention & treatment.This slide helps people to know about this disease.
World Allergy Week 2015: AIRWAY ALLERGIES The human and economic burdenJuan Carlos Ivancevich
Welcome! Join us during World Allergy Week 2015 and increase awareness of Airway Allergies - A Human and Economic Burden. There are many ways you can participate, and we hope you will explore this website, returning often, as it will continue to change.
The World Allergy Organization (WAO) is addressing the need for greater awareness and understanding of allergy topics as well as the exchange of ideas and collaboration in order to address treatment and quality-of-life issues related to the care of patients with allergic rhinitis and asthma.
Meningitis is a clinical syndrome characterized by inflammation of the meninges, the three layers of membranes that enclose the brain and spinal cord.
Infections of the central nervous system (CNS) can be divided into two broad categories:
Those primarily involving the meninges and those primarily confined to the parenchyma (encephalitis).
Meningitis is a clinical syndrome characterized by inflammation of the meninges, the three layers of membranes that enclose the brain and spinal cord.
Most cases of meningitis are caused by an infectious agent that has colonized or established a localized infection elsewhere in the host.
Classically described as the triad of fever, neck stiffness, and altered mental state; in reality, this picture is only seen in 44% of adults with bacterial meningitis and is even less specific in children
The skin is not only the largest organ of the body, but it also forms a living biological barrier with several functions.
Pyodermas are any pyogenic skin disease (has pus). Skin infections can be caused by bacteria (often Staphylococcal or Streptococcal) either invading normal skin, or affecting a compromised skin barrier
Some bacterial skin infections resolve without serious morbidity. However, skin infections can be severe and result in sepsis or death, particularly in vulnerable patient groups.
World Allergy Week 2015: AIRWAY ALLERGIES The human and economic burdenJuan Carlos Ivancevich
Welcome! Join us during World Allergy Week 2015 and increase awareness of Airway Allergies - A Human and Economic Burden. There are many ways you can participate, and we hope you will explore this website, returning often, as it will continue to change.
The World Allergy Organization (WAO) is addressing the need for greater awareness and understanding of allergy topics as well as the exchange of ideas and collaboration in order to address treatment and quality-of-life issues related to the care of patients with allergic rhinitis and asthma.
Meningitis is a clinical syndrome characterized by inflammation of the meninges, the three layers of membranes that enclose the brain and spinal cord.
Infections of the central nervous system (CNS) can be divided into two broad categories:
Those primarily involving the meninges and those primarily confined to the parenchyma (encephalitis).
Meningitis is a clinical syndrome characterized by inflammation of the meninges, the three layers of membranes that enclose the brain and spinal cord.
Most cases of meningitis are caused by an infectious agent that has colonized or established a localized infection elsewhere in the host.
Classically described as the triad of fever, neck stiffness, and altered mental state; in reality, this picture is only seen in 44% of adults with bacterial meningitis and is even less specific in children
The skin is not only the largest organ of the body, but it also forms a living biological barrier with several functions.
Pyodermas are any pyogenic skin disease (has pus). Skin infections can be caused by bacteria (often Staphylococcal or Streptococcal) either invading normal skin, or affecting a compromised skin barrier
Some bacterial skin infections resolve without serious morbidity. However, skin infections can be severe and result in sepsis or death, particularly in vulnerable patient groups.
Summary of updated information about the disease of Atopic dermatitis, aetiology, immunopathogenesis, main clinical features and dianostic criteria, concepts of managemnt of Atopic dermatitis including newest treatment trends.
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
Presentation by Professor Robyn Alders, Hub Roadmap Series Lead, at the Special Technical Session on 'Building a resilient biomedical disaster response: learning from the Covid-19 pandemic' organised by The Indian Council of Medical Research (ICMR).
This session was part of the 5th World Congress on Disaster Management (WCDM), which took place in New Delhi, India, in November 2021.
Influenza - History, Vaccination, and Public HealthLouise O' Flynn
A presentation exploring the history of Influenza, vaccination for influenza in Ireland, and the impact of Influenza on Public Health, public policy, and health promotion initiatives.
Authors: Tighearnan Corcoran, Stephanie Mulcair, Louise O' Flynn.
GRF One Health Summit 2012, Davos: Presentation by Prof. Cezmi A. Akdis - Director - Swiss Institute of Allergy and Asthma Research SIAF / President - European Academy of Allergy Clinical Immunology EAACI
Disaster risk reduction and nursing - human science research the view of surv...Global Risk Forum GRFDavos
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
Global alliance of disaster research institutes (GADRI) discussion session, A...Global Risk Forum GRFDavos
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
Towards a safe, secure and sustainable energy supply the role of resilience i...Global Risk Forum GRFDavos
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
Making Hard Choices An Analysis of Settlement Choices and Willingness to Retu...Global Risk Forum GRFDavos
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
The Relocation Challenges in Coastal Urban Centers Options and Limitations, A...Global Risk Forum GRFDavos
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
Involving the Mining Sector in Achieving Land Degradation Neutrality, Simone ...Global Risk Forum GRFDavos
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
Disaster Risk Reduction and Nursing - Human Science research the view of surv...Global Risk Forum GRFDavos
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
Training and awareness raising in Critical Infrastructure Protection & Resili...Global Risk Forum GRFDavos
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
IDRC Davos 2016 - Workshop Awareness Raising, Education and Training - Capaci...Global Risk Forum GRFDavos
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
Dynamic factors influencing the post-disaster resettlement success Lessons fr...Global Risk Forum GRFDavos
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
Consequences of the Armed Conflict as a Stressor of Climate Change in Colombi...Global Risk Forum GRFDavos
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
Disaster Risk Perception in Cameroon and its Implications for the Rehabilitat...Global Risk Forum GRFDavos
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
Systematic Knowledge Sharing of Natural Hazard Damages in Public-private Part...Global Risk Forum GRFDavos
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
Exploring the Effectiveness of Humanitarian NGO-Private Sector Collaborations...Global Risk Forum GRFDavos
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
Can UK Water Service Providers Manage Risk and Resilience as Part of a Multi-...Global Risk Forum GRFDavos
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
A Holistic Approach Towards International Disaster Resilient Architecture by ...Global Risk Forum GRFDavos
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
6th International Disaster and Risk Conference IDRC 2016 Integrative Risk Management - Towards Resilient Cities. 28 August - 01 September 2016 in Davos, Switzerland
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Allergy Asthma and One Health „The size of the problem“
1. Allergy Asthma and
One Health
„Thesize of theproblem“
Cezmi A. Akdis
Swiss Institute of Allergy and Asthma Research
(SIAF)
2. Allergies and Asthma
1’500’000’000 patients
300’000’000 asthma
250’000 deaths from asthma per year
10 % of all patients have severe disease
15 times more likely to use emergency services
Utilize 60% of the health costs
7. Increased prevalence of chronic noncommunicable disorders
including allergy and asthma with westernized life style.
The reduced exposure to diverse microbioma and physical inactivity may
impair immune regulatory mechanisms and immune tolerance to environment.
8. leaky barrier
breaking of tolerance
infections and microbiome
exposome
life style
genes
mechanisms
of being
clinically
healthy
despite
allergen
sensitization
Healthy
Allergic
molecular
events in
the facit
circle of
chronicity
and severity
diet
infections microbiome
induction of tolerance
strengthening of barriers
control of exposome
education
T. Bieber, R. Lauener, P-S Grendelmeier, C-T Hoffmann, C.A. Akdis
13. Barriers Related to Research Grants-I
• Lack of political awareness and low understanding
and priority setting for allergyepidemics
• Curative approaches and research for prevention
have not been efficientlysupportedso far
• Small quantities of grants have been given to
hypothesis-based research, although the real need is
large scale, non hypothesis based, in dept research,
which is now possible with the novel developments in
next generation DNA and RNA sequencing, exposome
analysis, and epigenetic analysis
14. Barriers Related to Research Grants-II
• Human research is receiving relatively less
funding in many grant giving bodies compared
to animal models
• Many major grant giving bodies had to
decrease their budgets during the last
yearsbecauseofgeneralfinancialproblems
• Negative results that are not published are
being repeated
15. Global Vision and Roadmap I
•Allergy and Asthma epidemic affects more than 1.5 billion patients
with a global rise in prevalence, as the most common chronic childhood
disease and highest health-care costs
•Effective policies and strategy development are needed to fill this gap
at the global, regional and national level
•Efforts to overcome unmet needs should focus on 4 main directions
Research and development
Better patient care at the global level
Increased public awareness
Allergies and Asthma in political agenda
16. Global Vision and Roadmap II
•A “Global Allergy and Asthma Fight Strategy” should be developed
•All stakeholders, such as specialists, primary care physicians, nurses,
dieticians, psychologists, pharmacists, patient organizations, educators,
industry, and policy makers should be involved
•A multidisciplinary and scientific approach should be used
•“One Health”concept that suggests systemic interconnections between
human, environment, animal health and food and water safetyshould be
integrated
•Next generation guidelines should be developed
•A World Allergy and Asthma integrated surveillance network should be
established
•Existing know-how from successful approaches in the past should be
utilized and implemented
21. Global Unmet Needs in Allergies and Asthma
•Pathomechanisms of allergic diseases are still not fully known
•There is a global burden of access to drugs and good patient care in
underdeveloped regions
•There is no established way of prevention of allergies
•There is no established way of curative treatment
•Biomarkers to subgroup patients, predict outcomes and follow
therapy response are needed
•Vaccine development against viruses that trigger exacerbations
should be supported
•Patient-tailored treatment should be strongly implemented
•Next generation global guidelines that consider individual needs,
regional differences and disease subgroups are needed
•A worldwide registry and regional biobanks for allergy and asthma
are needed